Wellness Franchise Opportunities

InvestmentJan, 14 2015

Piramal Pharma plans $40 million investment in technology

Piramal Enterprises' pharmaceutical solutions division has said it is planning to invest $40 million on new equipment and modern technologies.

By WI Bureau

New Delhi: Piramal Enterprises' pharmaceutical solutions division has said it is planning to invest $40 million on new equipment and modern technologies.

"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as anti-body drug conjugation (ADC), advanced flow reactor (ARF) and biocatalysis centre of excellence systems," the pharma major said in a statement.

The investment has been planned with a view to enhance related infrastructure to accommodate the new technologies and equipment.

In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure, the release added. Recently, the company completed a green field facility (USD 10 million) to double its Discovery Services capacity, and also approved a $20 million capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing, the release said.

PEL is one of the leading global players in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.

The company said it has secured four awards in three key categories of quality, reliability, and regulatory at the recent CMO Leadership Awards held in Boston, USA.New Delhi: Piramal Enterprises' pharmaceutical solutions division has said it is planning to invest $40 million on new equipment and modern technologies.

"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as anti-body drug conjugation (ADC), advanced flow reactor (ARF) and biocatalysis centre of excellence systems," the pharma major said in a statement.

The investment has been planned with a view to enhance related infrastructure to accommodate the new technologies and equipment.

In addition to the investment of $40 million in new equipment and technologies, the company will also augment related infrastructure, the release added. Recently, the company completed a green field facility (USD 10 million) to double its Discovery Services capacity, and also approved a $20 million capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing, the release said.

PEL is one of the leading global players in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.

The company said it has secured four awards in three key categories of quality, reliability, and regulatory at the recent CMO Leadership Awards held in Boston, USA.

Image: CorbisImages

Related: What made FMCG major Dabur to strategise combat move against Ramdev’s Patanjali

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Recommended For You

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.